Mechanism of Action of Prostate Stem Cell Antigen Targeted Antibody Therapy and its Relevance to Clinical Application in Prostate Cancer
Abstract
We have recently demonstrated that a monoclonal antibody against prostate stem cell antigen (PSCA) can exert anti-tumor activity in a xenograft animal model suggesting oncogenic activity of PSCA in prostate cancer. Therefore the our goal is to elucidate the role of PSCA in the development of prostate cancer. A better understanding of PSCA function and its antibody activity will enable rational patient selection and trial design all of which are particularly relevant to subsequent clinical trials of PSCA antibody. There were difficulties in using the LAPC9 xenograft cells to study the effect of suppressing PSCA but we have since moved ahead to perform an in vivo experiment to study the effect of knocking down PSCA in LAPC9 tumor cells. While the results showed no difference in tumor size we will repeat this experiment this time making sure that PSCA is greatly attenuated before innoculating the tumor cells back into mice. The exciting new data came from the in vitro study of overexpressing PSCA in cell lines. We showed that PSCA promote cell growth in prostate cancer cell line 22RV1 but not in normal cells PZ-HPV7. This results agree with previous data that PSCA is upregulated in prostate cancer. We have also engineered the gene targeting construct to make the human PSCA knockin mice and expect to generate this line in the next 6 month.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2008
- Accession Number
- ADA479732
Entities
People
- Chau Tran
- Robert Reiter
Organizations
- University of California, Los Angeles